The effects of treatment with broad-spectrum parenterally administered cephalosporins and cefuroxime, cefazolin, or nafcillin were compared in an experimental model of Staphylococcus aureus infective endocarditis, and the results in vivo were compared with the activities of the study drugs in vitro. After 3 days of treatment, all antimicrobial agents tested were more effective than no treatment in reducing the number of surviving bacteria in cardiac valve vegetations. Nafcillin was the most effective agent studied and was significantly more active than was ceftizoxime, ceftriaxone, cefotaxime, cefoperazone, cefuroxime, or cefazolin (P c 0.05). Cefpirome and ceftazidime were the most effective broad-spectrum cephalosporins. The outcome of treatment with cefpirome or ceftazidime was similar to that of treatment with nafcillin and significantly better than that of treatment with ceftizoxime or cefotaxime (P < 0.05). Treatment outcome correlated closely with the MICs of the antimicrobial agents for the study strain with the exception of ceftazidime, which was significantly more active in vivo in comparison with other agents than predicted by its MIC (P . 0.0003). When ceftazidime was excluded as an outlier, treatment outcome correlated with the MICs of the remaining study drugs (Spearman's correlation coefficient, 0.95; P . 0.0004), as well as with the estimated percentage of time during which the concentration of total drug (correlation coefficient, -0.85; P . 0.007) or free drug (correlation coefficient, -0.90; P c 0.003) exceeded the MIC. A consideration of total or free drug concentrations in relation to MICs did not significantly improve the correlation with outcome observed with the MICs alone.
Broad-spectrum cephalosporins are used widely in clinical practice. In general, these agents are more active in vitro than narrow-spectrum cephalosporins against gram-negative aerobic microorganisms, at the expense of variable decreases in antistaphylococcal activity (4) . Broad-spectrum cephalosporins are not the antimicrobial agents of choice for known monobacterial staphylococcal infection, but they are frequently prescribed as empiric broad-spectrum antimicrobial therapy in situations in which Staphylococcus aureus, either alone or in combination with other microorganisms, may be among the significant pathogens. Controlled clinical data directly comparing the efficacies of these newer cephalosporins in patients who have staphylococcal bacteremia are unavailable. Previous animal model studies suggested that, for ceftazidime and staphylococci, in vitro data correlate poorly with in vivo efficacy (1, 9) . The experimental endocarditis model of infection represents a stringent test of vivo antibacterial activity, is highly reproducible, and offers the advantages of quantitative endpoints under defined experimental conditions and the ability to simultaneously compare several treatments. This study was designed to compare the relative antistaphylococcal activities in vivo of newer cephalosporins, including cefuroxime, cefoperazone, cefpirome, ceftazidime, ceftizoxime, cefotaxime, and ceftriaxone, in a rabbit model of experimental endocarditis. Cefazolin and nafcillin were included as indicators of the relative effectiveness of standard therapies in this model. We additionally sought to determine the relationship between in vivo outcome of treatment and in * Corresponding author.
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vitro antibacterial activity as assessed by standard laboratory methods, and to test the hypothesis that ceftazidime is an outlier in this relationship.
MATERUILS AND METHODS
In vitro studies. Twenty-five isolates of S. aureus recovered from patients with infective endocarditis were stored in defribrinated sheep blood at -70°C until ready for use. Strains were thawed and subcultured on Trypticase soy agar (BBL Microbiology Systems, Cockeysville, Md.) containing 5% sheep blood before testing. A macrodilution method (11) was used for susceptibility testing with standard (5 x 105 CFU/ml) and high (5 x 10 CFU/ml) inoculum sizes. Organisms were prepared from overnight broth cultures and inoculated into serial twofold dilutions of antimicrobial agents in tryptic soy broth. Subcultures were made to confirm inoculum sizes and purity. Tubes were incubated for 24 h at 35'C in room air. The MIC was defined as the lowest concentration of antimicrobial agent with no visible growth of staphylococci. The MBC was determined by subculturing 100 ,ul of broth from the control tube, from the first tube containing visible growth, and from all tubes not containing visible growth and was defined as the lowest concentration of antimicrobial agent that resulted in a 3-log (99.9%) decrease of the original inoculum at 24 h (10) . For the strain chosen for in vivo experiments, the MIC of each of the study antimicrobial agents at the standard inoculum fell within the midrange of the 25 strains tested (data not shown). In vitro susceptibility testing of the study strain was performed as described above in fivefold replicates, and the average value was calculated as the geometric mean of the replicates. The study strain produced a type C staphylococcal 1-lactamase (6) .
In vivo studies. For each antimicrobial agent, concentrations in the serum of five healthy animals were assayed at 30 min and 1, 2, 4, 8, 12, and 24 h after a single antimicrobial dose. The doses used in the in vivo experiments were chosen to approximate the usual peak concentrations of the respective antimicrobial agents in the serum of humans receiving recommended doses (12) . A bioassay technique was used for all antimicrobial assays (15) .
Experimental catheter-associated aortic valve infective endocarditis was established by a modification of the method described by Garrison and Freedman (5) . In brief, New Zealand White rabbits (weight, >2 kg) were anesthetized with a mixture of ketamine and xylazine injected intramuscularly (i.m. Twenty-four hours after the intravenous injection of staphylococci, animals were placed in the following treatment groups: (i) 9 animals received no treatment; (ii) 15 animals received cefazolin (50 mg/kg of body weight) i.m. three times daily (t.i. Antimicrobial therapy was administered for 3 days. (3, 7, 14) . Correlation of treatment outcome with pharmacokinetic parameters and in vitro susceptibility was estimated by Spearman's rank correlation coefficient. To test the hypothesis that ceftazidime is an outlier in the relationship between in vitro susceptibility and treatment outcome, we examined the partial t statistic for the second variable in a bivariate linear regression model, where treatment outcome is the dependent variable, MIC is the first independent variable, and the second independent variable is 1 for ceftazidime and 0 otherwise. To test whether models including pharmacokinetic parameters improved the prediction of outcome over that obtained with the model using the MIC alone, we calculated the partial t statistic from standard (105 CFU/ml) and high (107 CFU/ml) inocula demonstrated little inoculum effect with this strain, with the exception of ceftazidime. Because of the discordance between the activities of ceftazidime in vitro and in vivo (see below), the susceptibility of the study strain was also tested substituting 50% rabbit serum as the diluent. The MICs of ceftazidime and other study antimicrobial agents were unchanged in rabbit serum (data not shown), suggesting that a potential interaction with unrecognized factors in rabbit serum was not responsible for the superior activity of ceftazidime in vivo.
In vivo studies. The concentrations of antimicrobial agents observed in vivo at the doses given are shown in Table 2 . Table 3 shows the results of treatment. Preliminary overall analysis revealed a highly significant difference among treatment groups (P < 0.0004). As assessed by the rate of clearance of bacteria from cardiac valve vegetations, all antimicrobial agents studied were more effective (P < 0.05) than no treatment. Nafcillin was the most effective agent and was significantly (P < 0.05) more effective than was ceftizoxime, cefotaxime, ceftriaxone, cefoperazone, cefuroxime, or cefazolin. Ceftazidime and cefpirome were similar in efficacy to nafcillin or cefazolin (P > 0.10) and were significantly more effective (P < 0.05) than was ceftizoxime, cefotaxime, or ceftriaxone. Differences in survival and in the proportion of valves sterilized after 3 days of treatment were not statistically significant between treatment groups.
A comparison of the rank order of the MICs of the study antimicrobial agents and treatment outcomes demonstrated a close correspondence between activities in vitro and in vivo, with the exception of ceftazidime, which was the least active drug in vitro but the second most effective drug in vivo (Table 1 ). Spearman's correlation coefficient comparing outcome with MIC for all study drugs was 0.49 (P not significant). As illustrated in Fig. 1 , however, ceftazidime was a highly significant outlier (P < 0.0003) in the otherwise apparent correlation between treatment outcome and susceptibility in vitro. Ceftazidime was therefore excluded from further analysis of the relationship between treatment outcome and in vitro or pharmacokinetic parameters for the remaining eight drugs.
Excluding ceftazidime, outcome was highly correlated with susceptibility in vitro as assessed by MICs using standard inoculum (Spearman's correlation coefficient, 0.95; P < 0.0004). Treatment outcome was also significantly correlated with the estimated percentage of time during which either the total drug concentration or the free drug concentration exceeded the MIC using the standard inoculum (correlation coefficients, -0.85 and -0.90, respectively; P c 0.007 and P < 0.003, respectively). Bivariate linear regression analysis with the MIC as the first independent (16) .
The observation of increased activity in vivo of ceftazidime extends the findings of Baker and Fass (1) (2) .
The results of the current study are consistent with recommendations that P-lactamase-stable penicillins or narrow-spectrum cephalosporins be the drugs of choice for serious methicillin-susceptible S. aureus infections. Broadspectrum cephalosporins were more effective than no treatment but, except for cefpirome and ceftazidime, were significantly less effective than nafcillin under these experimental conditions. The in vivo activity of cefpirome in this model paralleled its enhanced in vitro activity relative to those of other broad-spectrum cephalosporins against staphylococci. Ceftazidime was also highly effective in this model, but this observation should be extended with caution to staphylococcal infections in humans. The MIC of ceftazidime for S. aureus was not predictive of treatment outcome for this agent; treatment outcome for the study drugs other than ceftazidime correlated closely with the MIC.
